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Summary We investigated the effect of c-myb antisense phosphorothioate oligodeoxynucleotides [(S)ODNs]
and cisplatin (CDDP) combination on the human colon carcinoma cell line LoVo Dx both in vitro and in nude
mice bearing LoVo Dx solid tumour. We show that antisense (S)ODN treatment decreases c-myb mRNA and
protein expression, induces growth arrest in the GI phase ofthe cell cycle, and inhibits cell proliferation. In vivo
treatment with c-myb antisense (S)ODNs results in a reduction in tumour growth. A greater inhibition of cell
proliferation in vitro and a higher increase of tumour growth inhibition and growth delay in vivo were obtained
with the combination of (S)ODNs and CDDP than when the two agents were administered separately. This
comparative study, using the same tumour cell line in vitro and in vivo, suggests that c-myb antisense (S)ODNs
might be useful in the therapy of colon cancer in combination with antineoplastic drugs.
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The potential use of antisense oligodeoxynucleotides (ODNs)
as therapeutic agents in cancer treatment has recently
attracted considerable interest. As aberrant expression of
growth-promoting genes contributes to the growth advantage
of tumour cells, targeting such genes with antisense ODNs
might be useful in controlling the abnormal proliferation of
cancer cells (Calabretta, 1991). Indeed, ODNs complemen-
tary to oncogene-encoded mRNAs can inhibit proliferation
of tumour cell lines (Yokoyama and Imamoto, 1987; Negroni
et al., 1991; Raschell'a et al., 1982). In this regard, we
previously demonstrated that an oligodeoxynucleotide com-
plementary to the messenger RNA of c-myb proto-oncogene
inhibits in vitro cell growth of a human promyelocytic
leukaemia cell line (Citro et al., 1992).
The c-myb proto-oncogene encodes a DNA-binding
protein with transactivation properties that plays an
important regulatory role in cell proliferation and differentia-
tion (Shen-Ong, 1990). Expression of c-myb was first detected
in haematopoietic cells (Shen-Ong, 1990) and subsequently in
several human solid tumours, particularly in those originating
in colon mucosa (Alitalo et al., 1984; Torelli et al., 1987;
Ramsay et al., 1992). It was then demonstrated that c-myb
expression is important not only in haematopoietic prolifera-
tion and differentiation, but also in the proliferation of non-
haematopoietic cells (Calabretta and Nicolaides, 1992),
suggesting a more general role than previously thought. By
comparing normal, dysplastic and malignant colon tissue
samples from the same patient, it was found that c-myb
expression is higher in colonic tumours than in normal
mucosa (Torelli et al., 1987; Ramsey et al., 1992). This
suggests that c-myb may play a role in the malignant
transformation of colonic mucosa and that inhibition of c-
myb expression may supress, to some extent, proliferation of
neoplastic cells. Indeed, c-myb antisense ODNs have already
been used to inhibit cell proliferation in colon cancer lines.
However, only a partial suppression of cell proliferation was
observed (Melani et al., 1991), perhaps reflecting the
accumulation of alterations in the structure and function of
several oncogenes and anti-oncogenes during tumorigenic
conversion of normal colonic mucosa (Fearon and Vogel-
stein, 1990). Accordingly, complete suppression of tumour
cell proliferation may require inhibition of multiple growth-
promoting genes. Alternatively, the combination of onco-
gene-targeted ODNs with standard cytotoxic drugs might
represent a useful therapeutic approach to improving cancer
treatment. Only a few reports have so far concentrated on the
potentiating effect of antisense ODNs targeting growth-
promoting genes on chemotherapeutic drugs (Prins et al.,
1993; Nieborowska-Skorska et al., 1994).
With the aim of obtaining information that may lead to an
improved use of (S)ODNs in clinical trials, here we evaluated
the efficacy of the combination of c-myb antisense (S)ODNs
with an antineoplastic drug on the LoVo Dx human colon
carcinoma cell line in vitro and in vivo. For our study, we
chose the LoVo Dx model because, if compared with the
LoVo parental cell line, it presents a higher level of c-myb
expression (Melani et al., 1991). Specifically, we investigated
whether the inhibition of a growth-promoting gene such as c-
myb affected the antineoplastic activity of cisplatin (CDDP),
a chemotherapeutic agent widely used in the treatment of
several solid human malignancies (Rosenberg, 1985), includ-
ing colon carcinoma (Scheithauer et al., 1991; Rowinsky et
al., 1991).
Materials and methods
Cell culture
The LoVo Dx cell line resistant to doxorubicin (Dx) was
derived from a human colon adenocarcinoma (Grandi et al.,
1986). Dx resistance was induced by prolonged culture in
medium containing 1.7 gtM of doxorubicin. Cells were
cultured in Ham's F-12 medium supplemented with 10%
inactivated fetal calf serum (FCS), 2 mM glutamine,
0.04 mg ml-1 gentamycin, 1.7 gIM Dx and maintained in a
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humidified 95% air 5% carbon dioxide incubator at 37°C.
LoVo Dx cells were routinely subcultured every 7 days using
a 5 min exposure to 0.05% trypsin-EDTA solution and were
cultured for 2-4 weeks in drug-free medium before each
experiment.
Drug and oligodeoxynucleotides
Cisplatin (Platinex, Bristol Meyer, Syracuse, NY, USA), as
supplied for clinical use, was diluted in supplemented medium
to reach the desired final concentration. The solution was
freshly made up before each experiment. Cisplatin (CDDP)
sensitivity of LoVo Dx cells was determined by calculating
the CDDP dose that caused 50% inhibition (ICso value) of
LoVo Dx cell proliferation. Approximately 1 x 104 LoVo Dx
cells were plated in 24-well plates as described above, and
24 h later medium containing increasing drug concentration
(from 0.5 to 10 Mg ml-') was added. After 2 h drug exposure,
cells were washed and resuspended in drug-free medium. Six
days later, cells were harvested and viable cells (trypan blue
exclusion test) were counted. The dose of CDDP that caused
50% inhibition of LoVo Dx cell proliferation (2 Mg ml-') was
chosen for our experiments.
Phosphorothioate oligodeoxynucleotides (supplied from
Lynx Therapeutics, Hayward, CA, USA), were resuspended
at 5 mg ml-' in sterile saline solution and stored at -20°C in
small aliquots. (S)ODNs corresponding to the translation
initiation region of the human c-myb mRNA codons 2-7,
were used for in vitro and in vivo studies. The sequences
derived from the human c-myb cDNA (Majello et al., 1986),
were 5'-GCC CGA AGA CCC CGG CAC-3' and 5'-GTG
CCG GGG TCT TCG GGC-3' for the c-myb sense and
antisense 18 mer (S)ODNs respectively. In additional in vitro
experiments, we used a c-myb antisense ODN corresponding
to codons 2-6 and two three-base-mismatched derivatives
(5'-GTC CTG GGG TCG TCG-3' and 5'-GTG CGG GTG
CCC TTCG-3' respectively).
In vitro (S)ODNs and CDDP treatment
Cell proliferation studies Approximately 1 x 104 cells were
seeded in 24-well plates (Costar) and treated every 24 h with
10 ,UM c-myb sense or antisense (S)ODN for 3 consecutive days.
Control cells were cultured in the same conditions without
(S)ODNs. For CDDP and (S)ODN combinations, CDDP (at
the dose of2 Mug ml-') was added 24 h after seeding the cells in
culture and was removed 2 h later. c-myb sense or antisense
(S)ODNs (10 Mm) were added to the culture medium for 3
consecutive days after CDDP treatment. Quadruplicate
samples from each treatment were harvested with 0.05%
trypsin-EDTA solution; cell counts (Coulter Counter model
ZM, Kontron) and viability (trypan blue dye exclusion) were
determined daily until day 10 ofculture.
Isobologram analysis Approximately 1 x 104 cells were
seeded in 24-well plates (Costar) and after 24 h were treated
as follows: (a) CDDP at doses ranging from 1 to 6 Mg ml-'
for 2 h; (b) c-myb antisense (S)ODNs at doses ranging from
2.5 h to 20 pM every 24h for 3 consecutive days; (c) CDDP
at 1 and 2 Mg ml-' for 2h followed by c-myb antisense at 5
and 10 ,M every 24 h for 3 consecutive days. On days 5, 8
and 10 of cell culture, quadruplicate samples from each
treatment were harvested as above, counted and assayed for
viability. Then, isobologram analysis was performed to assess
the nature of the interaction between the two agents.
RNA extraction and reverse transcription-polymerase chain
reaction (RT-PCR) analyses
Total RNA was extracted from LoVo Dx cells by the
acid guanidium thiocyanate-phenol-chloroform technique
(Chomczynski and Sacchi, 1987). c-myb and ,B-actin mRNA
transcripts were detected by RT-PCR as described (Venturelli
et al., 1990; Citro et al., 1994). ,B-acTin expression was
evaluated as control of the amount of RNA used. c-myb
expression was detected with 3' and 5' primerscorresponding to
nucleotides 2466-2487 and2258-2279 respectively. The 3' and
5' primers, corresponding to nucleotides 885-905 and 600-
621 respectively, wereused forevaluation of,-actinexpression.
After 30 cycles, 10 Ml of amplification products was run on a
2% agarose gel and transferred to a nitrocellulose filter by
alkaline blotting. Filters were hybridised at 49°C using 5'-end-
labelled ([y32P]-ATP) oligonucleotide probes. ,B-Actin and c-
myb PCR products were detected with 32P-labelled probes
corresponding to nucleotides 795-815 and 2351-2400
respectively. After hybridisation, filters were washed and
exposed to X-ray films at -80°C. Results were quantitated
by a video densitometer (model 620, Bio Rad).
Western blotting
One to two million cells werelysed at4°C for 30 min incell lysis
buffer containing 2% sodium dodecyl sulphate (SDS), 20 mM
Tris-pH 8.0, 2 mM phenylnethylsulfonyl fluoride (PMSF) and
then sonicated. Equal amounts ofproteins were separated on a
12% SDS polyacrylamide gel. Transfer was performed in
glycine transfer buffer (192 mM glycine, 25 mM Tris pH 8.8,
20% v/v methanol) for 1.5 h at 100 V to nitrocellulose
(Immobilon PVDF membrane, Millipore Corporation, Bed-
ford, MA, USA). Western blotting was carried out with ECL
Western blotting kit (Amersham). Filters were blocked with
2% non-fat skim milk in TBS (20 mM Tris pH 8.2, 137 mM
sodium chloride) for 1 h at room temperature. Anti-Myb-
specific monoclonal antibody (UBI 05-175) was used at 1:1000
dilution in 1% non-fat skimmed milk in TBS containing 0.5%
Tween 20 for 2.5 h, washed three times for 20 min with TBS
and detected by horseradish peroxidase-conjugated anti-mouse
antibody (Bio-Rad, 172- 1011, Richmond, CA, USA) accord-
ing to the manufacturer's instructions. After three washings in
TBS containing 0.5% Tween 20, filters were incubated in a
luminol-based detection solution for 1 min and then exposed
for various times to Kodak X-OMAT AR film. To assess
protein amounts transferred into nitrocellulose membrane,
after stripping the c-Myb antibody, fl-actin, used as control,
was detected with an anti-human fl-actin MAb (clone JLA20,
Oncogene Science, NY, USA). Myb protein levels were
quantified by scanning the autoradiography films with a gel
densitometer scanner (Model 620, Bio Rad) and normalised to
,B-actin levels.
Cell cycle analysis
On days 1, 3 6 and 9 of cell culture, untreated, sense- or
antisense (S)ODN-treated cells were washed, harvested,
pooled and centrifuged at 130 g for 10 min. After two
washings in cold phosphate-buffered saline (PBS), cells were
fixed in 50% acetone-methanol (1:4, v/v) in PBS at 4°C for
at least 1 h before flow cytometric analysis. Approximately
2 x 105 fixed cells were stained with 400 MI of a solution
containing 75 kU ml-' RNAase (Sigma, St Louis, MO,
USA) and 50 Mg ml-' propidium iodide (Sigma) for 30 min
at room temperature. After filtration through an 80 gM nylon
mesh, DNA content of the samples was measured using a
FACScan cytofluorimeter (Becton Dickinson Sunnyvale, CA,
USA). For each sample, 20 000 events were analysed in
duplicate. The percentage of cells in the different cell cycle
phases was estimated by applying a mathematical model
(Fox, 1980) to the histograms by means of a Becton
Dickinson software package.
In vivo experiments
Athymic CD-1 nu/nu mice, 5-6 weeks old, were purchased
from the Charles River Laboratories (Calco, Italy). Mice
were kept in a laminar air-flow cabinet under specific
pathogen-free conditions. The LoVo Dx colon carcinoma
was established as a solid intramuscular tumour by injecting
0.2 ml of a suspension containing 2 x 106 viable cells in theCisplatin/c-myb antisense combination on LoVo Dx cell line
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leg muscle with the tumour being maintained by serial
passages in vivo at 3 week intervals. We chose the
intramuscular implant because it produces a more homo-
geneous tumour take and tumour growth than the
subcutaneous implant. In fact, 7-8 days after cell injection,
a tumour mass was evident in 100% of injected mice. Single-
cell suspensions were prepared from tumours by enzymatic
digestion as previously described (Arancia et al., 1991). Each
experimental group consisted of 10-12 animals. About 70
animals were used for a single experiment. CDDP treatment
was started at day 4 after tumour implant, by intraperitoneal
(i.p.) administration of 10% of the lethal dose (LD,o),
calculated according to the Spearman and Karber method
(Finney, 1964), subdivided into three daily injections of
3.3 mg kg day-' (days 4-6). (S)ODNs were administered
intravenously (i.v.) at a dose of 1 mg/mouse day-' (days 7-
14). The following schedules were employed: (a) antisense
(S)ODNs x 8 days; (b) sense (S)ODNs x 8 days; (c) CDDP x 3
days; (d) CDDP x 3 days followed by antisense (S)ODNs x 8
days; (e) CDDP x 3 days followed by sense (S)ODNs x 8
days. Mice in the control group received 0.2 ml of 0.9%
sodium chloride solution i.p. x 3 days and i.v. x 8 days.
Tumour growth was monitored daily by caliper measure-
ments of length and width. Tumour weight was calculated as
follows (Geran et al., 1972):
tumor weight (mg) = [length (mm) x width (mm)2]/2
The effect of treatment on tumour growth was assessed
using the following end points: (1) tumour weight inhibition
(TWI%); (2) tumour growth delay (T-C, days); (3) median
time (days) of appearance of palpable tumours in treated and
control group.
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Figure 1 Expression of c-myb mRNA (a) and protein (b) in
LoVo Dx cells treated with c-myb (S)ODNs. LoVo Dx cells were
untreated (C) or exposed for 3 consecutive days to 10 M c-myb
sense (S) or antisense (A) oligodeoxynucleotides starting 24h after
seeding the cells in culture. To evaluate the expression of c-myb
mRNA, cells were harvested at the end of treatment, and total
RNA was isolated and divided into two equal portions that were
separately amplified by RT-PCR with c-myb and ,B-actin-specific
primers. Western blotting analysis was performed 30, and 72h
after the beginning of treatment with (S)ODNs. Representative of
three independent experiments with similar results.
Statistical analysis
Statistical differences from values of controls and of other
groups were assessed by the Mann-Whitney non-parametric
method.
Results
c-myb mRNA and protein levels in c-myb (S)ODNs-treated
LoVo Dx cells
We evaluated c-myb mRNA expression in LoVo Dx cells
immediately after treatment with c-myb sense or antisense
(S)ODNs (Figure la). In cells treated with c-myb antisense
(S)ODNs there was a marked reduction in c-myb mRNA
levels (about 80%, by densitometric analysis and normal-
isation to P-actin mRNA). No decrease in c-myb mRNA
levels was detected after treatment with c-myb sense
(S)ODNs. Western blot analysis was then performed to
assess Myb protein levels in (S)ODN-treated cells. Eight
hours after the beginning of (S)ODN treatment, there was no
difference in Myb protein levels between control, sense- or
antisense-treated cells (data not shown). A decrease in Myb
protein level was detected after 30 h of exposure to antisense
(S)ODNs (39% decrease relative to controls, by densitometry
analysis). A greater reduction in Myb protein levels (65%
decrease relative to controls, by densitometry analysis) was
evident after 72 h treatment (Figure lb).
Effect of c-myb (S)ODNs on LoVo Dx cell proliferation
The ability of c-myb (S)ODNs to inhibit proliferation of
LoVo Dx cells was assessed by direct cell countings, and by
cell cycle analysis. Cell counts of cultures treated with 18-mer
c-myb antisense (S)ODNs indicated a reduction in cell
proliferation at day 3, and a more pronounced inhibition
(50-60% of reduction) from the days 6-10 of culture
(Figure 2a). Treatment with sense (S)ODNs did not affect
proliferation of LoVo Dx cells (Figure 2a). The 18-mer c-myb
(S)ODNs had no significant effect on LoVo Dx cell survival,
in the same experimental conditions. A clonogenic assay
performed at each day of growth, starting from days 2-10,
demonstrated that cell survival was not affected in the case of
c-myb sense treatment whereas after c-myb antisense
treatment the decrease in cell survival was 25% (on day 2),
30% (on day 5) and 30% (on day 10) (data not shown).
Additional experiments were performed with a 15-mer c-myb
antisense ODN and with two three-base-mismatched
derivatives, one of which included (see Materials and
methods) the 4-G motif reported to non-specifically inhibit
proliferation ofcertain cell lines (Yaswen et al., 1993; Burgess
et al., 1995). The c-myb antisense (S)ODNs inhibited LoVo
Dx cell proliferation, whereas neither mismatched sequence
had appreciable effects (Figure 2b).
Cell cycle phases distribution of LoVo Dx cells exposed to
sense or antisense c-myb (S)ODNs was evaluated by flow
cytometry (Figure 3). The analysis was performed on days 1,
3, 6 and 9 of growth in liquid culture. Treatment with c-myb
antisense (S)ODNs resulted in accumulation of cells in the G,
phase of the cell cycle with a simultaneous reduction of cells
in the S-phase, already detectable on the third day of culture.
No clear effect on the G2 +M compartment was observed.
Cell cycle distribution of LoVo Dx cells treated with c-myb
sense (S)ODNs was indistinguishable from that of untreated
cells (data not shown). Together, these results indicate that
treatment with c-myb antisense (S)ODNs induces inhibition
of cell proliferation, evident only several days after exposure
to the (S)ODNs.
Effect of c-myb antisense (S)ODNs and DDP treatment on
LoVo Dx cell proliferation and c-myb mRNA levels
Figure 4a shows the effect of CDDP and c-myb antisense
(S)ODNs given alone or in combination on LoVo Dx cell
proliferation. Incubation for 2 h with CDDP followed by a 3
day c-myb antisense (S)ODN treatment led to an increase in
sensitivity of LoVo Dx cells to CDDP. In fact, as evaluated
after 6-8 days of culture, the (S)ODN/CDDP combinationCisplatin/c-myb antisense combination on LoVo Dx cell line
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produced an approximately 80% inhibition ofcell proliferation
whereas CDDP and (S)ODNs, used individually, produced
approximately a 50% and 55% inhibition respectively. The
antiproliferative effect of the various compounds was
correlated with levels of c-myb mRNA, detected by RT-
PCR. Only the treatment with c-myb antisense (S)ODNs,
individually or in combination with CDDP, induced a
decrement ofc-myb mRNA levels (Figure 4b).
Isobologram analysis
To define the type of the interaction and the interaction index
(Berembaum, 1981, 1985) between CDDP and c-myb
x
CO) (0)
U-
0 5
Growth days
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b
antisense (S)ODNs in combination we determined, initially,
the effect ofincreasing doses of CDDP (Figure 5a) and c-myb
antisense (S)ODNs (Figure 5b) given separately, in terms of
mean cell number at the 5, 8 and 10 days of growth. Then,
we evaluated the effect, in terms of mean cell number at the
same days of growth, of the two agents given in combination
(Figure 5c) according to the schedules reported in the
Materials and methods section. For each value in Figure
6c, the interaction index I (Berembaum, 1981) was calculated
as follows:
I = Ac/AE + Bc/BE
where Ac and Bc are the dosages of the agents used in
combination eliciting a certain effect while AE and BE are
respectively the dosages of the agents A and B eliciting the
same effect when administered alone.
Single doses of CDDP and c-myb antisense (S)ODNs
producing the same effect on cell growth at the same day, in
terms of mean cell number, were determined, interpolating
the results from Figure 5a and b. When the dose of the agent
used alone and producing the same effect of the combination
exceeds the highest experimental dose, this maximum dose
value is used to calculate the interaction index. Table I shows
the interaction index for the combination CDDP/c-myb
antisense calculated as above from the data reported in
Figure 5c. According to Berembaum (1981), the evaluation of
the type and level of interaction among agents can be
approached in terms of interaction index (I), defined as the
sum of the ratios between dosages of the agent which, when
used in combination or alone, induces the same effect in
terms of cell survival or growth. The interaction index can
assume the following values:
I < 1 indicates synergistic interaction;
I = 1 indicates additive interaction;
I> 1 indicates antagonistic interaction.
As the interaction index values reported in Table I ranging
around 1 and taking into account the uncertainty related to
the experimental data (Gentile et al., 1992), the interaction
index value for additivity can be included in the range 0.8-
1.2. Therefore, from our experimental data we can conclude
0
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Figure 2 Effect of c-myb (S)ODNs on LoVo Dx cells
proliferation. (a) Treatment with 18-mer c-myb sense (A) or
antisense (U) (S)ODNs (10jIM) was performed for 3 consecutive
days starting 24h after seeding the cells in culture. Control cells
(-) were left untreated. Cell counts and viability were determined
daily until day 10 of culture. Representative of three different
experiments with similar results. (b) Treatment with a 15-mer c-
myb antisense ODN (M) or two three-base-mismatched (S)ODNs
(A, 0), and cell counts of untreated (0) and (S)ODN-treated
cells were as described above. Representative of three different
experiments with similar results. Both in (a) and (b), each value is
an average+standard error (s.e.) of four different determinations
within the same experiment. When not shown, the standard error
is smaller than the symbol.
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Figure 3 Cell cycle distribution of LoVo Dx cells treated with c-
myb antisense (S)ODNs. Treatment with c-myb (S)ODNs (10,MM)
was carried out for 3 consecutive days starting 24h after seeding
the cells in culture. DNA content analysis was performed on days
1, 3, 6 and 9 of culture. At least duplicate samples were analysed
for each day; 20000 events were scored for each sample. The
effect ofc-myb sense (S)ODNs on cell cycle phase distribution was
not reported as it was similar to that observed for control,
untreated cells. -U-, antisense G1 phase; -LI-, contol GI phase;
-A-, antisense S-phase; -A-, control S-phase; ---, antisense
G2+M phase; -0-, control G2+M phase. Results represent the
mean+standard error obtained from three independent experi-
ments with different (S)ODN preparations.
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that the combination between CDDP and c-myb antisense
produces an additive interaction.
In vivo studies
The anti-tumour activity of c-myb (S)ODNs and CDDP,
alone or in combination, was evaluated in nude mice bearing
LoVo Dx solid tumours (Table II). Administration of c-myb
sense (S)ODNs was completely ineffective against LoVo Dx,
the mean weight of the tumour in the treated group being the
0
x
0)
C-
Growth days
b
P-acTin c-myb
10
24h
72-
144 h
same as that of the control group. Treatment with antisense
(S)ODNs, on the other hand, inhibited local tumour growth,
as compared with the untreated group. In fact, at the end of
treatment (14 days post implant) tumour weights of control
and antisense groups were 197+27 mg (mean+s.d.) and
120+35 mg respectively (P<0.01). No toxicity was noted;
the modest loss in body weight (5% reduction) noted during
the treatment, was made up after treatment. The response of
T-, 30 x r.
u
0
a b c d a b c d a b c d
CDDP c-myb AS CDDP +
c-myb AS
Figure 5 Dose-dependent effect of CDDP, c-myb antisense
(S)ODNs and CDDP/c-myb antisense (S)ODNs combination on
LoVo Dx cell growth. In (a), (b) and (c) cells were treated 24h
after seeding according to the following schedules. (a) CDDP for
2h: a, I Mgml- ; b, 2Mugml-1; c, 4pgml 1; d, 6pgml-1 b c-
myb antisense for 3 consecutive days: a, 2.5MMday-; b,
5pMday 1; c, I0OMday'-; d, 20 Mday-. (c) CDDP for 2h
followed by c-myb antisense for 3 consecutive days: a, CDDP
I ugml-l +c-myb antisense 5gMday-l; b, CDDP 1pugml
I +c-
myb antisense 10jMMday-l; c, CDDP 2jgml- 1 +c-myb antisense
5jMday-l; d CDDP 2 igml-l +c-myb antisense 10MMday-l.
Cell counts were determined as described in Material and
methods at days 5 (L ), 8 ( ) and 10 (_) of cell culture.
Representative of two separate experiments with similar results.
Each value is an average+s.e. of four different determinations
within the same experiment.
Table I Interaction Index of the combination CDDP+c-myb
antisense (S)ODNs
Growth days
Combination 5 8 10
CDDP 1 jg ml-' +AS 5 gM 0.98 0.99 1.18
CDDP 1 ig ml- +AS 10 gM 0.96 0.84 0.98
CDDP 2 ,ig ml-' +AS 5 ,M 1.26 1.03 0.98
CDDP 2Mg ml- +AS lO gM 1.08 1.01 0.98
1 2 3 4 5 6
Figure 4 Effect of c-myb antisense (S)ODNs and CDDP on
LoVo Dx cell proliferation and c-myb mRNA levels. (a) c-myb
antisense (S)ODNs were added to the culture medium at
10yMday-' for 3 consecutive days. CDDP treatment
(2jgml- for 2h) was started 24h after seeding the cells in
culture. For antisense-drug combinations, c-myb antisense
(S)ODNs were added to the culture medium at 10pMday-' for
3 consecutive days after CDDP treatment (2pgml-l for 2h).
Control cells were cultured in the same conditions without
(S)ODNs. Treatment with c-myb sense (S)ODNs was without
effects and treatment with c-myb sense/CDDP was similar to
CDDP alone (not shown). ---, Control; -U-, antisense; -A-,
cisplatin; -El-, cisplatin-.antisense. Representative of three
independent experiments with similar results. Each value is an
average+s.e. of four different determinations within the same
experiment. When not shown, the standard error is smaller than
the symbol. (b) To assess c-myb mRNA levels, cells were
harvested at the indicated times from the beginning of
treatment, and total RNA was isolated and divided into two
equal portions (0.5 Mg each) separately amplified by RT-PCR (30
cycles) with c-myb and ,B-acTin-specific primers. Following
hybridisation with 32P-labelled specific probes, c-myb and ,B-actin
blots were exposed to X-ray films for 4 and 2h respectively. Lanes
are as follows: (1) untreated cells; (2) c-myb sense (S)ODN-treated
cells; (3) c-myb antisense (S)ODN-treated cells; (4) CDDP-treated
cells; (5) CDDP-c-myb sense (S)ODN-treated cells; (6) CDDP-c-
myb antisense (S)ODN-treated cells. Results are from a
representative experiment.
Table II Anti-tumour effects of c-myb antisense (S)ODNs and
CDDP on LoVo Dx implanted in nude mice
TWt T-Cc Body weightd Drug
Schedulea (% ±s.d.) (days±s.d.) loss (%) deathse
Antisense 39±10 3.5+0.5 5 0/20
Sense 8+2 0.5+0.1 4 0/20
CDDP 41 +12 5±1.1 13 2/24
CDDP
plus antisense 62+21 9+2 12 2/24
CDDP
plus sense 35+6 5+1 15 1/24
aMice received: c-myb sense or antisense (S)ODNs (1 mg/mouse -
day-' i.v.) on days 7-14 after tumour implant; CDDP i.p.
(3.3 mg kg day-', i.p.) on days 4-6; CDDP (3.3 mg kg day-1, i.p.)
on days 4-6 followed by c-myb sense or antisense (S)ODNs (1 mg/
mouse day-', i.v.) on days 7-14 after tumour implant. bTumour
weight inhibition: mean tumour weight ofthe treated groups divided
by mean tumourweight ofthe control group, minus 1 x 100. cTumour
growth delay: median time in days for the treated (T) groups to reach
250 mg minus median time in days for the control (C) group to reach
the same size. dMaximum body weight loss during the experimental
period. eDeaths ocurring in treated mice 1 week after the end of
treatment were considered as due to drug toxicity. Results represent
the mean of two independent experiments.
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LoVo Dx tumour to CDDP treatment was similar to that
observed after antisense (S)ODN injection, the mean tumour
weight being 118 +22 mg. The CDDP/(S)ODNs combination
determined a marked local control of tumour growth, with a
TWI of 62% and a growth delay of9 days being obtained. In
particular, tumour weights measured after treatment with
CDDP and antisense (S)ODNs were significantly smaller
(80+23 mg) than those from the untreated, CDDP, or
antisense (S)ODN-treated groups. Statistical analysis showed
a significant difference in tumour weight in mice receiving no
treatment or treated with CDDP and/or (S)ODNs. In fact, a
P<0.01 was observed comparing the tumour weight of
CDDP/(S)ODN-treated mice vs that in the untreated group;
a P<0.05 was obtained comparing the tumour weight of
CDDP/(S)ODN- and (S)ODN- or CDDP-treated groups.
The toxicity observed in combination experiments, both in
terms of animal death and body weight loss, was super-
imposable to that observed after CDDP treatment.
Discussion
The purpose of this study was to evaluate the efficacy of the
CDDP/c-myb antisense (S)ODN combination on the in vitro
and in vivo growth of LoVo Dx, a human colon carcinoma
cell line with high levels of c-myb expression (Melani et al.,
1991). It has been postulated that the c-myb gene is involved
in the pathogenesis of colon carcinoma (Alitalo et al., 1984;
Torelli et al., 1987; Ramsay et al., 1991), suggesting that the
ability to selectively down-regulate this expression, by use of
antisense ODNs, might have therapeutical potential. An
obstacle to a widespread use of unmodified antisense ODNs
is represented by their short half-life in biological systems
(Stein et al., 1988). Accordingly, for both in vitro and in vivo
experiments, we used phosphorothioate oligodeoxynucleo-
tides, which are more resistant to cleavage by nucleases (Stein
et al., 1988; Agrawal et al., 1991). Moreover, (S)ODNs are
characterised by a good solubility in aqueous solution and an
efficient hybridisation with mRNA, making them possible
therapeutic agents for eventual clinical application.
We selected c-myb antisense (S)ODNs corresponding
either to codons 2-7 or 2-6 as the region immediately
downstream from the initiation codon is commonly targeted
in antisense experiments and as we were previously able to
inhibit proliferation of a human leukaemia cell line by
targeting the same mRNA region (Citro et al., 1992). Here,
we demonstrated that c-myb expression plays an important
role in LoVo Dx cell proliferation, both in vitro and in vivo.
We observed that a down-regulation of c-Myb protein is
evident as early as 30 h after the beginning of treatment when
cell proliferation was only marginally affected. The early
down regulation of c-Myb protein levels after antisense
(S)ODN treatment most likely reflects the short half-life (30-
60 min) of c-Myb mRNA and protein (Thiele et al., 1988;
Lipsick and Boyle, 1987), and is consistent with the
interpretation that the down-regulation of c-myb protein
expression is not the result but the cause of the reduction in
cell proliferation.
We also found that in vivo treatment of LoVo Dx tumour
with c-myb antisense (S)ODNs reduces the tumour growth, in
terms of both tumour weight inhibition and tumour growth
delay. These data agree with those of other authors,
confirming the in vivo antiproliferative effect of c-myb
antisense (S)ODNs and its potential usefulness for the
systemic treatment of solid and non-solid tumours
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